ZNF331

Summary

ZNF331 (zinc finger protein 331, HGNC:15489) is a protein-coding gene on chromosome 19q13.42, encoding Zinc finger protein 331 (Q9NQX6). May be involved in transcriptional regulation.

This gene encodes a zinc finger protein containing a KRAB (Kruppel-associated box) domain found in transcriptional repressors. This gene may be methylated and silenced in cancer cells. This gene is located within a differentially methylated region (DMR) and shows allele-specific expression in placenta. Alternative splicing and the use of alternative promoters results in multiple transcript variants encoding the same protein.

Source: NCBI Gene 55422 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 24 total
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• Transcription factor: yes — 18 downstream targets (CollecTRI)
• MANE Select transcript: NM_001079906

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15489
Approved symbol	ZNF331
Name	zinc finger protein 331
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	RITA, ZNF463, ZNF361
Ensembl gene	ENSG00000130844
Ensembl biotype	protein_coding
OMIM	606043
Entrez	55422

Gene structure

Transcript identifiers

Ensembl transcripts: 85 — 77 protein_coding, 5 protein_coding_CDS_not_defined, 3 retained_intron

ENST00000253144, ENST00000449416, ENST00000502248, ENST00000502616, ENST00000504033, ENST00000504493, ENST00000504940, ENST00000505426, ENST00000505949, ENST00000509069, ENST00000509585, ENST00000511154, ENST00000511567, ENST00000511593, ENST00000512387, ENST00000513265, ENST00000513929, ENST00000513999, ENST00000514374, ENST00000647573, ENST00000648122, ENST00000648236, ENST00000648397, ENST00000648511, ENST00000649326, ENST00000649780, ENST00000649816, ENST00000650177, ENST00000876850, ENST00000876851, ENST00000876852, ENST00000876853, ENST00000876854, ENST00000876855, ENST00000876856, ENST00000876857, ENST00000876858, ENST00000876859, ENST00000876860, ENST00000876861, ENST00000876862, ENST00000876863, ENST00000876864, ENST00000876865, ENST00000876866, ENST00000876867, ENST00000924926, ENST00000924927, ENST00000924928, ENST00000924929, ENST00000924930, ENST00000924931, ENST00000924932, ENST00000924933, ENST00000924934, ENST00000924935, ENST00000924936, ENST00000924937, ENST00000924938, ENST00000924939, ENST00000924940, ENST00000924941, ENST00000924942, ENST00000924943, ENST00000924944, ENST00000924945, ENST00000924946, ENST00000924947, ENST00000924948, ENST00000924949, ENST00000949158, ENST00000949159, ENST00000949160, ENST00000949161, ENST00000949162, ENST00000949163, ENST00000949164, ENST00000949165, ENST00000949166, ENST00000949167, ENST00000949168, ENST00000949169, ENST00000949170, ENST00000949171, ENST00000949172

RefSeq mRNA: 16 — MANE Select: NM_001079906 NM_001079906, NM_001079907, NM_001253798, NM_001253799, NM_001253800, NM_001253801, NM_001317113, NM_001317114, NM_001317115, NM_001317116, NM_001317117, NM_001317118, NM_001317119, NM_001317120, NM_001317121, NM_018555

CCDS: CCDS33102

Canonical transcript exons

ENST00000449416 — 6 exons

Exon	Start	End
ENSE00001303154	53555845	53555908
ENSE00001375565	53539216	53539282
ENSE00001388872	53576697	53580269
ENSE00001426577	53569304	53569385
ENSE00002073291	53538145	53538296
ENSE00002436541	53571604	53571730

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 97.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.7766 / max 431.6262, expressed in 1488 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177348	3.3154	347
177343	2.9244	284
177336	2.4469	1119
177328	1.5663	631
177342	0.6113	92
177329	0.6055	270
177338	0.4293	196
177340	0.3911	118
177341	0.2951	80
177337	0.2157	98

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower lobe of lung	UBERON:0008949	97.08	gold quality
sperm	CL:0000019	95.23	gold quality
right lung	UBERON:0002167	95.18	gold quality
adenohypophysis	UBERON:0002196	95.18	gold quality
left ovary	UBERON:0002119	95.04	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.98	gold quality
pituitary gland	UBERON:0000007	94.91	gold quality
male germ cell	CL:0000015	94.89	gold quality
cauda epididymis	UBERON:0004360	94.47	gold quality
type B pancreatic cell	CL:0000169	94.40	gold quality
left uterine tube	UBERON:0001303	93.77	gold quality
right ovary	UBERON:0002118	93.59	gold quality
ovary	UBERON:0000992	92.77	gold quality
vena cava	UBERON:0004087	92.54	gold quality
omental fat pad	UBERON:0010414	92.41	gold quality
peritoneum	UBERON:0002358	92.39	gold quality
pericardium	UBERON:0002407	92.25	gold quality
sural nerve	UBERON:0015488	92.05	gold quality
mucosa of stomach	UBERON:0001199	91.98	gold quality
pons	UBERON:0000988	91.95	gold quality
tibial artery	UBERON:0007610	91.89	gold quality
superficial temporal artery	UBERON:0001614	91.87	gold quality
popliteal artery	UBERON:0002250	91.87	gold quality
corpus epididymis	UBERON:0004359	91.63	gold quality
upper lobe of lung	UBERON:0008948	91.45	gold quality
upper lobe of left lung	UBERON:0008952	91.40	gold quality
mucosa of urinary bladder	UBERON:0001259	91.32	gold quality
adipose tissue of abdominal region	UBERON:0007808	91.20	gold quality
olfactory bulb	UBERON:0002264	91.06	gold quality
lung	UBERON:0002048	91.01	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-GEOD-106540	yes	1819.86
E-GEOD-81547	yes	1758.12
E-CURD-135	yes	1756.27
E-CURD-79	yes	1352.53
E-MTAB-8381	yes	755.43
E-GEOD-135922	yes	28.98
E-HCAD-1	yes	28.77
E-CURD-122	yes	25.12
E-MTAB-6678	yes	24.27
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

18 targets.

Target	Regulation
ACTR3	Repression
BAX	Activation
BBC3	Activation
CCNB1	Repression
CDC25C	Repression
CDK1	Repression
DDX5	Repression
DSTN	Repression
EIF5A	Repression
PMAIP1	Activation
PNPT1	Activation
SET	Repression
SSBP1	Activation
STAM	Repression
TP53
TSC1
UQCRFS1	Repression
ZNF91

JASPAR motifs

Motif	Name	Family
MA1726.1	ZNF331	More than 3 adjacent zinc fingers
MA1726.2	ZNF331	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:27852650

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

90 targeting ZNF331, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-5010-3P	99.83	70.60	2357

Literature-anchored findings (GeneRIF, showing 9)

• Unique expression of a 3.4-kbp transcript of ZNF331 is described in thyroid adenoma cell lines with 19q13 aberrations. (PMID:14610350)
• ZNF331 possesses important functions for the suppression of gastric carcinogenesis as a novel functional tumor-suppressor gene (PMID:22370639)
• A high negative correlation between promoter DNA methylation and gene expression was observed for CDO1, ZNF331 and ZSCAN18 in gastrointestinal tumors. (PMID:24948044)
• Methylation of ZNF331 Promotes Cell Invasion and Migration in Human Esophageal Cancer (PMID:25929867)
• the present study provides initial evidence that RITA upregulates the expression level of IRE1a by increasing the stability of IRE1alpha mRNA in irradiated mtp53-expressing cervical cancer cells (PMID:26134873)
• this study shows that ZNF331 gene may be associated with pathogenesis of asthma (PMID:27842724)
• Results show that ZNF331 is frequently methylated in human colorectal cancer, and the expression of ZNF331 is regulated by promoter region methylation. Methylation of ZNF331 is a poor prognostic marker of colorectal cancer. (PMID:29075358)
• Study have showed the potential of promoter methylation of ZNF331 as a biomarker for colorectal cancer detection. Further data provide evidence indicating a trend towards poorer prognosis for patients with ZNF331 methylation. (PMID:29854011)
• Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer. (PMID:33992091)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

Zinc finger protein 331 — Q9NQX6 (reviewed: Q9NQX6)

Alternative names: C2H2-like zinc finger protein rearranged in thyroid adenomas, Zinc finger protein 361, Zinc finger protein 463

All UniProt accessions (9): Q9NQX6, D6RH27, E7EPG5, E7EPT0, E7ETJ5, E7EV14, E7EWU7, Q71QC5, Q71QC9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation. May play a role in spermatogenesis.

Subcellular location. Nucleus.

Tissue specificity. Testis specific.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (16): NP_001073375, NP_001073376, NP_001240727, NP_001240728, NP_001240729, NP_001240730, NP_001304042, NP_001304043, NP_001304044, NP_001304045, NP_001304046, NP_001304047, NP_001304048, NP_001304049, NP_001304050, NP_061025 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050589	Ikaros_C2H2-ZF	Family

Pfam: PF00096, PF01352, PF13912

UniProt features (17 total): zinc finger region 12, cross-link 2, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQX6-F1	76.53	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 109, 400

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway
R-HSA-9843940	Regulation of endogenous retroelements by KRAB-ZFP proteins

MSigDB gene sets: 137 (showing top): NAGASHIMA_NRG1_SIGNALING_UP, RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP, KIM_GERMINAL_CENTER_T_HELPER_DN, MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_DN, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GRYDER_PAX3FOXO1_TOP_ENHANCERS, CHEN_HOXA5_TARGETS_9HR_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GRYDER_PAX3FOXO1_ENHANCERS_KO_DOWN, REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, RAF_UP.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, DIDO1_TARGET_GENES, E2F5_TARGET_GENES

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Regulation of endogenous retroelements	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

838 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF331	CDO1	P78513	559
ZNF331	GNAS	Q5JWF2	500
ZNF331	ZDBF2	Q9HCK1	492
ZNF331	DCLK1	O15075	488
ZNF331	DPRX	A6NFQ7	454
ZNF331	MCTS2	A0A3B3IRV3	447
ZNF331	NRDE2	Q9H7Z3	433
ZNF331	SPIDR	Q14159	431
ZNF331	ZSCAN18	Q8TBC5	423
ZNF331	MEST	Q5EB52	419
ZNF331	SFRP1	Q8N474	417
ZNF331	SNU13	P55769	412
ZNF331	BBX	Q8WY36	406
ZNF331	KBTBD12	Q3ZCT8	404
ZNF331	CC2D1A	Q6P1N0	404

IntAct

20 interactions, top by confidence:

A	B	Type	Score
ZNF331	IPO8	psi-mi:“MI:0915”(physical association)	0.710
ZNF331	USP9Y	psi-mi:“MI:0914”(association)	0.530
Trim28	FTH1	psi-mi:“MI:0915”(physical association)	0.400
C8orf33	ZNF331	psi-mi:“MI:0915”(physical association)	0.370
MAPK6	ZNF331	psi-mi:“MI:0915”(physical association)	0.370
ZNF331	NR4A1	psi-mi:“MI:0915”(physical association)	0.370
PTK2	ZNF331	psi-mi:“MI:0915”(physical association)	0.370
SURF2	ZNF331	psi-mi:“MI:0915”(physical association)	0.370
IPO8	BIN1	psi-mi:“MI:0914”(association)	0.350
ZNF331	TRIM24	psi-mi:“MI:0914”(association)	0.350
MRPS9	SLC25A20	psi-mi:“MI:0914”(association)	0.350
ZNF331	GSR	psi-mi:“MI:0914”(association)	0.350
FHL2	ZNF331	psi-mi:“MI:0915”(physical association)	0.000
ZNF212	ZNF331	psi-mi:“MI:0915”(physical association)	0.000
ZNF331	ZNF408	psi-mi:“MI:0915”(physical association)	0.000
APP	ZNF331	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (103): ZNF331 (Affinity Capture-MS), FAM172A (Affinity Capture-MS), FBXO38 (Affinity Capture-MS), CTNNBL1 (Affinity Capture-MS), KIF7 (Affinity Capture-MS), LRP4 (Affinity Capture-MS), IPO8 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), LRP1B (Affinity Capture-MS), NIN (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), CCDC6 (Affinity Capture-MS), FBLN5 (Affinity Capture-MS), SHCBP1 (Affinity Capture-MS), SORL1 (Affinity Capture-MS)

ESM2 similar proteins: A2RRD8, A6NHJ4, A6NK75, B4DU55, O75346, P0DPD5, P15621, P17030, P17039, P52737, Q0VGE8, Q14588, Q147U1, Q15928, Q2M3X9, Q3KNS6, Q494X3, Q4R6C2, Q5HYK9, Q5R5Q6, Q5R5S6, Q5REA0, Q5REK1, Q60585, Q61751, Q6ECI4, Q6P9Y7, Q6ZN19, Q6ZNA1, Q7Z3V5, Q86T29, Q86WZ6, Q8N141, Q8N7K0, Q8N9F8, Q8NA42, Q8NCK3, Q8NDQ6, Q8NEM1, Q8WV37

Diamond homologs: A0A1W2PQL4, A2RRD8, A2VDQ7, A6NHJ4, A6NK75, A6NN14, A6NNF4, A6NP11, B4DX44, B4DXR9, E9PW05, O14628, O43345, O75290, O75346, O75373, O75820, P0CB33, P0CJ79, P0DKX0, P10755, P17032, P17035, P52738, Q02386, Q03923, Q03936, Q05481, Q08AN1, Q09FC8, Q0VGE8, Q14586, Q14593, Q147U1, Q15928, Q3MIS6, Q3SXZ3, Q494X3, Q4R6C2, Q5HY98

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — NPC.

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	9
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1649 predictions. Top by Δscore:

Variant	Effect	Δscore
19:53522043:G:GT	donor_gain	1.0000
19:53522043:G:T	donor_gain	1.0000
19:53522610:C:A	acceptor_gain	1.0000
19:53522611:G:A	acceptor_gain	1.0000
19:53539283:GT:G	donor_loss	1.0000
19:53569299:CCTA:C	acceptor_loss	1.0000
19:53569302:A:AG	acceptor_gain	1.0000
19:53569302:A:AT	acceptor_loss	1.0000
19:53569303:G:GA	acceptor_gain	1.0000
19:53569303:GC:G	acceptor_gain	1.0000
19:53569303:GCT:G	acceptor_gain	1.0000
19:53569303:GCTC:G	acceptor_gain	1.0000
19:53569303:GCTCT:G	acceptor_gain	1.0000
19:53569381:CCCAG:C	donor_gain	1.0000
19:53569382:CCAG:C	donor_gain	1.0000
19:53569383:CAG:C	donor_gain	1.0000
19:53569384:AG:A	donor_gain	1.0000
19:53569385:GG:G	donor_gain	1.0000
19:53569386:G:GA	donor_loss	1.0000
19:53569386:G:GG	donor_gain	1.0000
19:53571598:TTTCA:T	acceptor_loss	1.0000
19:53571599:TTCA:T	acceptor_loss	1.0000
19:53571600:TCA:T	acceptor_loss	1.0000
19:53571601:CAGG:C	acceptor_loss	1.0000
19:53571602:A:AG	acceptor_gain	1.0000
19:53571602:AG:A	acceptor_gain	1.0000
19:53571603:G:GA	acceptor_loss	1.0000
19:53571603:G:GG	acceptor_gain	1.0000
19:53571603:GG:G	acceptor_gain	1.0000
19:53571603:GGGT:G	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000009240 (19:53508974 G>GCA), RS1000066515 (19:53508651 A>G), RS1000075940 (19:53535164 C>T), RS1000087379 (19:53550444 T>A), RS1000196410 (19:53565529 A>T), RS1000228129 (19:53520772 G>A,T), RS1000237946 (19:53520624 G>C), RS1000302801 (19:53565771 C>G,T), RS1000370799 (19:53559992 A>G), RS1000385610 (19:53516608 A>G,T), RS1000400903 (19:53559727 A>C,G), RS1000431858 (19:53559563 A>C,G), RS1000466492 (19:53544511 C>A,G), RS1000560452 (19:53519870 C>G,T), RS1000561389 (19:53523717 C>A)

Disease associations

OMIM: gene MIM:606043 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzene	affects expression, increases expression	3
torcetrapib	increases expression	2
aristolochic acid I	increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
geraniol	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
perfluorooctanoic acid	decreases expression	1
cupric oxide	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
abrine	increases expression	1
jinfukang	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Air Pollutants, Occupational	increases expression	1
Arsenic	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Lead	decreases expression	1
Nickel	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Vitamin E	decreases expression	1
Zinc	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW33	HEK293 eGFP-ZNF331	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.